Treatment of Nicotine Dependence and Acute Depression

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00186446
Recruitment Status : Completed
First Posted : September 16, 2005
Results First Posted : April 4, 2017
Last Update Posted : April 4, 2017
Information provided by (Responsible Party):
Alan Schatzberg, Stanford University

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Conditions: Major Depressive Disorder
Nicotine Dependence
Intervention: Drug: bupropion and smoking cessation behavioral intervention

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
Bupropion and Smoking Cessation Behavioral Intervention Medication for depression and behavioral intervention for smoking cessation

Participant Flow:   Overall Study
    Bupropion and Smoking Cessation Behavioral Intervention

  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Bupropion and Smoking Cessation Behavioral Intervention No text entered.

Baseline Measures
   Bupropion and Smoking Cessation Behavioral Intervention 
Overall Participants Analyzed 
[Units: Participants]
[Units: Years]
Mean (Standard Deviation)
 44.35  (10.0) 
Sex: Female, Male 
[Units: Participants]
Count of Participants
Female      10  50.0% 
Male      10  50.0% 
Race (NIH/OMB) 
[Units: Participants]
Count of Participants
American Indian or Alaska Native      0   0.0% 
Asian      2  10.0% 
Native Hawaiian or Other Pacific Islander      0   0.0% 
Black or African American      0   0.0% 
White      17  85.0% 
More than one race      0   0.0% 
Unknown or Not Reported      1   5.0% 
Region of Enrollment 
[Units: Participants]
Count of Participants
United States   20 

  Outcome Measures

1.  Primary:   Hamilton Depression Scale Score   [ Time Frame: baseline to week 10 ]

2.  Primary:   Cessation of Smoking   [ Time Frame: Week 10 ]

3.  Primary:   Can Depression and Smoking Cessation be Treated Simultaneously   [ Time Frame: Dropouts over course of study ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: aimee-noelle swanson
Organization: Stanford University
phone: 650-736-4559

Responsible Party: Alan Schatzberg, Stanford University Identifier: NCT00186446     History of Changes
Other Study ID Numbers: GSK 103341
First Submitted: September 13, 2005
First Posted: September 16, 2005
Results First Submitted: October 18, 2016
Results First Posted: April 4, 2017
Last Update Posted: April 4, 2017